Vaka Sunumu: Konversiyon Bulguları Eşliğinde Korpus Kallosum İnfarktı
Yıl 2019,
Cilt: 2 Sayı: 2, 22 - 24, 31.07.2019
Öner Avınca
,
Mahmut Yaman
Abdullah Şen
Ömer Damar
,
Mahmut Taş
Öz
Amaç:Yirmi üç yaşında konversiyon bulgular eşliğinde korpus kallozum infarktı saptanan bir kadın hasta, klinik laboratuvar ve radyolojik bulgular eşliğinde sunuldu.
Olgu: Daha öncesinde herhangi bir hastalığı olmayan hasta, 15 gün önce başarılı sezeryan operasyonu geçirmiş. Hastanın başvuru günü başlayan görmede bozukluk, görme bozukluğu nedenli yere yığılma, ellerde titreme ve anlamsız kelimeler söyleme gibi semptomları üzerine acil servisimize başvurmuştur. Hastanın acil serviste yapılan kan tetkiklerinde anlamlı bulguya rastlanmadı. Hastanın serebral MRG venografisi ve serebral difüzyon MRG’si çekildi. Serebral difüzyon MRG’sinde korpus kallozum spleniumu düzeyinde (en geniş yerinde ML 16mm) AP 10,5mm boyutlarında ölçülen difüzyon kısıtlılığı gösteren infarktla uyumlu lezyon görüldü.
Sonuç: Korpus kallozum anormallikleri sonucu gelişen klinik belirtiler değişkenlik göstermektedir. Olguların yaklaşık üçte birinde ise psikiyatrik tablolar gelişmektedir. Ancak saf psikiyatrik bulgular ile başlayan korpus kallozum infarktı literatürde nadiren gözlenmektedir. Bu vaka konversiyon bulgularla eş zamanlı korpus kallozum enfraktı görülmesinden dolayıyazılmıştır.
Kaynakça
- REFERENCES1. Marschilok C: Update on insulin pump therapy. School Nurse News. 2007, 12-3
- 2. Tuncel E, İmamoğlu, Ali R, Ozkalemkaş F, Erturk E, Arınık A: Comparison of Metabolic Effects of Continuous Subcutaneous İnsulin İnfusion Treatment With Conventional İnsulin Treatment in Type I diabetes Mellitus. Turkish Journal of Endocrinology, 1997, 1:18-23
- 3. De vries JH, Snoek FJ,Kostense PJ,Masurel N, Heine RJ; Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and İntensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002; 25 (11): 2074-80.
- 4. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidance base. For the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care.2002 25(3):593-8
- 5. Raskin P, Bode BW, Marks JB, Hirsch IB,Weinstein RL, Mc Gill jb, Peterson GE,Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily. İnjection therap are equally effective in type 2 diabetes:a ranndomized,paralel-group, 24 week study. Diabetes Care. 2003 ;26(29): 2598-603
- 6. Dr. Ercan TUNCEL Surekli Ciltaltı İnsulin İnfuzyon Tedavisi Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa.5-9 Eylül 2007
- 7. Mastrotara JJ, Cooper K, Shah R. Early clinical experience with an integrated continuous glucose sensor/insulin pump platform. Diabetes Res Clin Pract. 2006. Suppl 2:S156-9.
A Case Report: Corpus Callosum Infarct Associated With The Conversion Finding
Yıl 2019,
Cilt: 2 Sayı: 2, 22 - 24, 31.07.2019
Öner Avınca
,
Mahmut Yaman
Abdullah Şen
Ömer Damar
,
Mahmut Taş
Öz
Aim: A 23-year-old female patient diagnosed corpus callosum infarction with conversion findings was presented with the clinical laboratory and radiographic findings.
Case: The patient who had no previous illness had a successful cesarean operation 15 days ago. The patient came to our emergency service due to the current symptoms such as impaired vision, collapse due to the disorder in sight, tremoring hands, and saying nonsense words. No significant findings were found in the blood tests at the emergency service performed on the patient. Cerebral MRI venography and cerebral diffusion MRI were tested on the patient. Cerebral diffuse MRI of the patient showed an infarct compatible lesion with diffuse limitation measured with the dimensions of AP 10.5 mm (ML 16 mm at its widest point) in the level of the corpus callosum splenium.
Conclusion: The clinical indications that result from corpus callosum abnormalities vary. In approximately one-third of patients, psychiatric tables develop. However, corpus callosum infarction, which begins with pure psychiatric findings, is rarely observed in the literature. This case was written due to the presence of concomitant corpus callosum inflation with conversion findings.
Kaynakça
- REFERENCES1. Marschilok C: Update on insulin pump therapy. School Nurse News. 2007, 12-3
- 2. Tuncel E, İmamoğlu, Ali R, Ozkalemkaş F, Erturk E, Arınık A: Comparison of Metabolic Effects of Continuous Subcutaneous İnsulin İnfusion Treatment With Conventional İnsulin Treatment in Type I diabetes Mellitus. Turkish Journal of Endocrinology, 1997, 1:18-23
- 3. De vries JH, Snoek FJ,Kostense PJ,Masurel N, Heine RJ; Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and İntensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002; 25 (11): 2074-80.
- 4. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidance base. For the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care.2002 25(3):593-8
- 5. Raskin P, Bode BW, Marks JB, Hirsch IB,Weinstein RL, Mc Gill jb, Peterson GE,Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily. İnjection therap are equally effective in type 2 diabetes:a ranndomized,paralel-group, 24 week study. Diabetes Care. 2003 ;26(29): 2598-603
- 6. Dr. Ercan TUNCEL Surekli Ciltaltı İnsulin İnfuzyon Tedavisi Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa.5-9 Eylül 2007
- 7. Mastrotara JJ, Cooper K, Shah R. Early clinical experience with an integrated continuous glucose sensor/insulin pump platform. Diabetes Res Clin Pract. 2006. Suppl 2:S156-9.
Toplam 7 adet kaynakça vardır.